Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
| Autor: | Iman Karimzadeh, Fatemeh Saghafi, Adeleh Sahebnasagh, Solomon Habtemariam, Seyed Ruhollah Mousavinasab, Amirreza Roostaei Firozabad, Zohreh Akhoundi Meybodi, Mohsen Gholinataj Jelodar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Time Factors Placebo lcsh:Infectious and parasitic diseases law.invention 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacotherapy Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans lcsh:RC109-216 030212 general & internal medicine Prospective Studies Young adult Prospective cohort study Clinical status business.industry COVID-19 Hydroxychloroquine Levamisole Middle Aged COVID-19 Drug Treatment Clinical trial 030104 developmental biology Infectious Diseases Treatment Outcome SARS-CoV2 Female business medicine.drug Research Article |
| Zdroj: | BMC Infectious Diseases BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021) |
| ISSN: | 1471-2334 |
| Popis: | Background Levamisole has shown clinical benefits in the management of COVID-19 via its immunomodulatory effect. However, the exact role of Levamisole effect in clinical status of COVID-19 patients is unknown. We aimed to evaluate the efficacy of Levamisole on clinical status of patients with COVID-19 during their course of the disease. Methods This prospective, double-blind, randomized controlled clinical trial was performed in adult patients with mild to moderate COVID-19 (room-air oxygen saturation > 94%) from late April 2020 to mid-August 2020. Patients were randomly assigned to receive a 3-day course of Levamisole or placebo in combination with routine standard of care. Results With 25 patients in each arm, 50 patients with COVID-19 were enrolled in the study. Most of the study participants were men (60%). On days 3 and 14, patients in Levamisole group had significantly better cough status distribution when compared to the placebo group (P-value = 0.034 and 0.005, respectively). Moreover, there was significant differences between the two groups in dyspnea at follow-up intervals of 7 (P-value = 0.015) and 14 (P-value = 0.010) days after receiving the interventions. However, no significant difference in fever status was observed on days 1, 3, 7, and 14 in both groups (P-value > 0.05). Conclusion The results of the current study suggest that Levamisole may improve most of clinical status of patients with COVID-19. The patients receiving Levamisole had significantly better chance of clinical status including cough and dyspnea on day 14 when compared to the placebo. However, the effect-size of this finding has uncertain clinical importance. Trial registration The trial was registered as IRCT20190810044500N7 (19/09/2020). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink